Latest Hotspot

Argenx announces EU approval for subcutaneous VYVGART® to treat Generalized Myasthenia Gravis

24 November 2023
3 min read

argenx SE, an international immunology firm dedicated to enhancing the life quality of those dealing with profound autoimmune disorders, declared that VYVGART (efgartigimod alfa), a subcutaneous injection, has been green-lighted by EC to pair with standard therapy. This is for addressing generalized myasthenia gravis among adult patients exhibiting positive anti-acetylcholine receptor antibody.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件, Teams

描述已自动生成

In August 2022, VYVGART IV was initially greenlit by the EC. Post the endorsement, VYVGART has gained approval across Europe for both IV and self-administered SC use. This sanction holds for all 27 European Union member countries, including Iceland, Norway, and Liechtenstein. argenx is dedicated to collaborating with regional health bodies to ensure patient reach for VYVGART SC in these areas.

"Our dedication to offering an assortment of effective, cutting-edge treatments for individuals with autoimmune disorders is evident in this approval. We are jubilant to bring this second formulation to the European gMG community, a little more than a year after VYVGART IV received its first approval," stated Anant Murthy, the EMEA General Manager of argenx.

Murthy further added, "Having two formulations at disposal, including the one that patients can self-administer at home, empowers individuals afflicted with gMG to opt for the therapy that aligns better with their lifestyle. This underscores the personalized treatment strategy brought forward by VYVGART."

The approval from EC came on the heels of a favorable suggestion from the Committee for Medicinal Products for Human Use, and it pivots on the encouraging outcomes from the Phase 3 ADAPT-SC study. The efficacy of VYVGART SC was proven in the ADAPT- SC trial by showcasing a decrease in anti-AChR antibody concentrations on par with those of VYVGART IV in adult gMG patients. The ADAPT-SC served as a connective study to the Phase 3 ADAPT research, which laid the foundation for VYVGART IV's approval in Europe in August 2022.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of November 18, 2023, there are 16 investigational drugs for the FcRn target, including 29 indications, 38 R&D institutions involved, with related clinical trials reaching 214, and as many as 8107 patents.

VYVGART SC is a SC injectable formulation of efgartigimod alfa, a human IgG1 antibody fragment marketed for intravenous use as VYVGART. It is formulated with recombinant human hyaluronidase PH20, Halozyme’s ENHANZE® drug delivery technology, to facilitate SC injection delivery of biologics. In binding to the neonatal Fc receptor (FcRn), VYVGART results in the reduction of circulating IgG autoantibodies. VYVGART SC was approved in the United States in June 2023 and is marketed as VYVGART® Hytrulo.

图形用户界面, 文本, 应用程序

描述已自动生成

What are DHFR inhibitors and how do you quickly get the latest development progress?
What are DHFR inhibitors and how do you quickly get the latest development progress?
24 November 2023
The development of dihydrofolate reductase inhibitors has always been challenging. dihydrofolate reductase inhibitors have therapeutic applications in cancer, malaria, and protozoan infections.
Read →
Exploring KT-333's R&D successes and its clinical results at the 2023 ASH
Exploring KT-333's R&D successes and its clinical results at the 2023 ASH
23 November 2023
The latest clinical findings of KT-333 will be unveiled at the 2023 ASH Congress, setting the stage for subsequent investigations.
Read →
What are DHODH inhibitors and how do you quickly get the latest development progress?
What are DHODH inhibitors and how do you quickly get the latest development progress?
23 November 2023
DHODH inhibitors are drugs inhibiting the enzyme DHODH crucial in DNA and RNA production, disrupting cell growth.
Read →
First patient received ALE.C04 treatment in Alentis Therapeutics' Phase 1/2 study for HNSCC
Latest Hotspot
3 min read
First patient received ALE.C04 treatment in Alentis Therapeutics' Phase 1/2 study for HNSCC
23 November 2023
The first patient was treated with ALE.C04 in a Phase 1/2 study by Alentis Therapeutics, aimed at treating Head and Neck Squamous Cell Carcinoma (HNSCC).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.